Free Trial

Arcellx Q2 2023 Earnings Report

Arcellx logo
$68.13 +0.55 (+0.81%)
As of 01/31/2025 04:00 PM Eastern

Arcellx EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.68
Beat/Miss
Beat by +$0.18
One Year Ago EPS
N/A

Arcellx Revenue Results

Actual Revenue
$14.30 million
Expected Revenue
$82.38 million
Beat/Miss
Missed by -$68.08 million
YoY Revenue Growth
N/A

Arcellx Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Arcellx Earnings Headlines

Stifel Nicolaus Remains a Buy on Arcellx Inc (ACLX)
A new coin is elbowing its way to the top of the crypto world
With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only set to be released from its constraints … it could be about to explode. Trump has vowed to roll back Biden’s “crusade against crypto” on his first day in office.
Cantor Fitzgerald Predicts Arcellx FY2025 Earnings
See More Arcellx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcellx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcellx and other key companies, straight to your email.

About Arcellx

Arcellx (NASDAQ:ACLX), together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

View Arcellx Profile

More Earnings Resources from MarketBeat